

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****Prospective Grant of an Exclusive Patent License: Antibody-Based Therapy for the Treatment of CD20 Expressing Lymphomas**

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Heart, Lung, and Blood Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Retargeted Therapeutics, a corporation incorporated under the laws of the state of Delaware.

DATES: Only written comments and/or applications for a license which are

received by the National Heart, Lung, and Blood on or before June 8, 2020 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an exclusive patent license should be directed to: Vidita Choudhry, Ph.D. Technology Transfer Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479, phone number (301)–594–4095, or vidita.choudhry@nih.gov.

SUPPLEMENTARY INFORMATION:**INTELLECTUAL PROPERTY**

NIH ref No.	Title	Patent application No.	Filing date	Issued patent No.	Issue date
E-758-2013-0-US-01 ..	Antibody Targeting Cell Surface Deposited Complement Protein C3d and Use Thereof.	61/924,967	January 8, 2014	
E-758-2013-1-PCT-01	Antibody Targeting Cell Surface Deposited Complement Protein C3d and Use Thereof.	PCT/US2015/010620	January 8, 2015	
E-758-2013-1-US-02 ..	Antibody Targeting Cell Surface Deposited Complement Protein C3d and Use Thereof.	15/110,577	July 8, 2016	10,035,848	July 31, 2018.
E-758-2013-1-CA-03	Antibody Targeting Cell Surface Deposited Complement Protein C3d and Use Thereof.	2936346	January 8, 2015	
E-758-2013-1-EP-04 ..	Antibody Targeting Cell Surface Deposited Complement Protein C3d and Use Thereof.	15701442.4	January 8, 2015	3092252	September 18, 2019.
E-758-2013-1-US-05 ..	Antibody Targeting Cell Surface Deposited Complement Protein C3d and Use Thereof.	16/047,929	July 27, 2018	
E-025-2019-0-US-01 ..	Antibody Targeting Cell Surface Deposited Complement Protein C3d and Use Thereof.	62/945,569	December 9, 2019 ..		

Intellectual property listed here includes all U.S. and foreign patents and applications claiming priority to any member of the aforementioned applications.

The patent rights in these inventions have been assigned or exclusively licensed to the Government of the United States of America.

The prospective exclusive license territory may be worldwide and in fields of use that may be limited to use of anti-C3d monoclonal antibodies (mAbs) to potentiate anti-tumor activity of anti-CD20 mAbs for the treatment of B-cell lymphomas.

The aforementioned Patents and Patent applications cover technology directed to development of anti-C3d antibody or antibody fragments to re-target cells that have escaped from existing mAbs therapy and to potentiate the anti-tumor activity of therapeutic mAbs and eliminate antigen loss variants.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Heart, Lung, and Blood Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the

requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: May 14, 2020.

Bruce D. Goldstein,

Director, Office of Technology Transfer and Development, National Heart, Lung, and Blood Institute.

[FR Doc. 2020–11036 Filed 5–21–20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed).

Date: June 23, 2020.

Time: 1:30 p.m. to 3:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F58,

Rockville, MD 20892, (Telephone Conference Call).

Contact Person: Mario Cerritelli, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3F58, Rockville, MD 20852, 240-669-5199, cerritem@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: May 18, 2020.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-11059 Filed 5-21-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Electrical Signaling, Ion Transport, and Arrhythmias Study Section, June 10, 2020, 10:00 a.m. to June 10, 2020, 06:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on May 12, 2020, 85 FR 28022.

This notice is being amended to change the meeting start time from 11:00 a.m. to 10:00 a.m. The meeting is closed to the public.

Dated: May 18, 2020.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-11058 Filed 5-21-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the SINGLE-SITE AND PILOT CLINICAL TRIALS REVIEW COMMITTEE, June 24, 2020, 08:00 a.m. to June 25, 2020, 05:00 p.m., National Institute of Health (NIH), Rockledge 1, 6705 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on May 18, 2020, 85 FR 29732. The NHLBI Initial/Integrated Review Group meeting is being

amended to change the meeting start time to 9:00 a.m. and end time to 3:00 p.m. This two-day meeting to be held on June 24-25, 2020 will be a teleconference meeting. The meeting is closed to the public.

Dated: May 19, 2020.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-11125 Filed 5-21-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review Amended; Notice of Meeting

Notice is hereby given of a change in the meeting of the Cardiovascular Differentiation and Development Study Section, June 11, 2020, 10:00 a.m. to June 11, 2020, 07:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD, 20892 which was published in the **Federal Register** on May 12, 2020, 85 FR 28022.

This notice is being amended to change the meeting start time from 11:00 a.m. to 10:00 a.m. The meeting is closed to the public.

Dated: May 18, 2020.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-11063 Filed 5-21-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Committee to the Director, National Institutes of Health.

The meeting will be held as a teleconference call only and is open to the public to dial-in for participation. Individuals who plan to dial-in to the meeting and need special assistance or other reasonable accommodations to do so, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Advisory Committee to the Director, National Institutes of Health.

Date: May 26, 2020.

Time: 1:00 p.m. to 2:00 p.m.

Agenda: ACD to review and approve concept clearances for the Rapid Acceleration of Diagnostics (RADx) program to develop COVID-19 testing technologies, which is part of NIH's response to the COVID-19 pandemic.

Place: National Institutes of Health, Building 1, One Center Drive, Bethesda, MD 20892, (Telephone Conference Call), 800-369-1912, Access Code: 1019627.

Contact Person: Gretchen Wood, Staff Assistant, National Institutes of Health, Office of the Director, One Center Drive, Building 1, Room 126, Bethesda, MD 20892, 301-496-4272, Woodgs@od.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <http://acd.od.nih.gov>, where an agenda and any additional information for the meeting will be posted when available.

This notice is being published less than 15 days prior to the meeting due to scheduling difficulties.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: May 18, 2020.

Natasha M. Copeland,

Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2020-11061 Filed 5-21-20; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant